CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
cyclophosphamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00683670
NCT00683670Phase 1Completed
CompareCT.gov

Mature Dendritic Cell Vaccination Against gp100 in Patients With Advanced Melanoma

University of Pennsylvania·interventional·Posted May 23, 2008·Updated Jun 29, 2025

In Brief

A Phase 1 clinical trial evaluating cyclophosphamide and Mature dendritic cell vaccine for Melanoma. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 23, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 18.1 years ago

Interventions

cyclophosphamidedrug

Mature dendritic cell vaccinebiological